Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03352245 |
Recruitment Status :
Completed
First Posted : November 24, 2017
Results First Posted : May 21, 2021
Last Update Posted : May 21, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Neoplasm Malignant | Behavioral: Prescribed Activity | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Assessing the Feasibility of a Patient-centered Activity Regimen in Patients With Advanced Stage Lung Cancer |
Actual Study Start Date : | November 26, 2018 |
Actual Primary Completion Date : | May 24, 2020 |
Actual Study Completion Date : | May 24, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Intervention Group
Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
|
Behavioral: Prescribed Activity
Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2) |
No Intervention: Control Group
Usual care group will receive standard of care management from their Oncologist.
|
- Overall Step Count [ Time Frame: baseline to 12 weeks ]Participants will wear a Fitbit wrist band that will record step count.
- Number of Weeks Participants Adhered to Step Count Recommendations [ Time Frame: baseline to 12 weeks. ]Exercise Adherence will be defined as (the number of weeks a subject follows the activity prescription)/(the number of "usable" weeks). A week is considered "usable" if 5/7 days of step counts are available, and days with <200 steps/day are considered not usable.
- Dyspnea [ Time Frame: change from pre- to post-intervention (week 12) ]Assessed via self-report using the Modified Medical Research Council. Dyspnea Scale, a single-item scale scored 0-4; higher score indicates worse dyspnea.
- Depression [ Time Frame: change from pre- to post-intervention (week 12) ]Assessed via self-report using the Patient Health Questionnaire, Depression Module (PHQ-9). a 9-item questionnaire that assesses depressive symptoms over the preceding two weeks. Each item is scored 0-3 (0 = "Not at all"; 1 = "Several days"; 2 = "More than half of days"; 3 = "Nearly every day"). A total score is calculated by taking the sum of questions 1-9, and a higher score indicates worse depression.
- Change in Quality of Life: Global Health Status [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales:
Global health status/Quality of Life (QoL) scale, range 0-100, higher score = better quality of life.
- Change in Quality of Life: Physical Functioning [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measure physical functioning.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Role Functioning [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures role functioning.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Emotional Functioning [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures emotional functioning.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Fatigue [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures fatigue.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Cognitive Functioning [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures cognitive functioning.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Nausea/Vomiting [ Time Frame: change from pre- to post-intervention (week 12) ]Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures nausea and vomiting The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Pain [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures pain.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Social Functioning [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures social functioning.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Dyspnea [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure dyspnea.
The range of score is 0-100; higher score = higher symptoms burden.
- Change in Quality of Life: Insomnia [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure insomnia.
The range of score is 0-100; higher score = better functioning.
- Change in Quality of Life: Appetite Loss [ Time Frame: change from pre- to post-intervention (week 12) ]Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure appetite loss The range of score is 0-100; higher score = higher symptoms burden.
- Change in Quality of Life: Constipation [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure constipation.
The range of score is 0-100; higher score = higher symptoms burden.
- Change in Quality of Life: Diarrhea [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure diarrhea.
The range of score is 0-100; higher score = higher symptoms burden.
- Change in Quality of Life: Financial Difficulties [ Time Frame: change from pre- to post-intervention (week 12) ]
Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure financial difficulties.
The range of score is 0-100; higher score = higher symptoms burden.
- Moderate Aerobic Exercise [ Time Frame: baseline to 12 weeks ]The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.
- Vigorous Aerobic Exercise [ Time Frame: baseline to 12 weeks ]The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes.
- Change in C-reactive Protein (CRP) [ Time Frame: change from pre- to post-intervention (week 12) ]The investigators will obtain serum CRP, a marker of inflammation.
- Change in Leptin Level [ Time Frame: change from pre- to post-intervention (week 12) ]The investigators will obtain serum leptin, a marker of glucose control. .
- Change in Insulin Level [ Time Frame: change from pre- to post-intervention (week 12) ]The investigators will obtain serum insulin level, a measure of glucose control.
- Programmed Death - Ligand [ Time Frame: change from pre- to post-intervention (week 12) ]The investigators will collect soluble PD- L1, a novel cancer marker.
- Programmed Cell Death (PD-1) [ Time Frame: change from pre- to post-intervention (week 12) ]The investigators will collect soluble PD- 1, a novel cancer marker.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologic evidence of advanced non-small cell stage lung cancer (NSCLC)
- Approval of the treating clinician
- Adult patients (age >21 years) willing to wear a FitBit® device (FitBit, Inc., San Francisco, CA)
- Access to a smartphone, agree to receive twice/daily text messages for 12 weeks (including any costs), and willingness to download the FitBit application to their smartphone.
- Low activity level as judged by a brief physical activity questionnaire (i.e., <150 minutes/week of moderate-intensity exercise, <75 minutes/week of vigorous aerobic exercise, or an equivalent combination).
Exclusion Criteria:
- Memory impairment (as judged by the treating clinician)
- Communication impairment (as judged by the treating clinician)
- Treating clinician's request not to alter physical activity
- Physical inability to safely walk (as judged by the treating clinician)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03352245
United States, Connecticut | |
Yale University | |
New Haven, Connecticut, United States, 06510 |
Principal Investigator: | Brett Bade, M.D. | Yale University |
Documents provided by Yale University:
Responsible Party: | Yale University |
ClinicalTrials.gov Identifier: | NCT03352245 |
Other Study ID Numbers: |
2000022225 1P50CA196530-01 ( U.S. NIH Grant/Contract ) |
First Posted: | November 24, 2017 Key Record Dates |
Results First Posted: | May 21, 2021 |
Last Update Posted: | May 21, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Neoplasms Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Lung Diseases Respiratory Tract Diseases |